September 21st, 2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

Read More »
August 4th, 2021

Shear Insights: Brian Wamhoff Recognized as one of the PharmaVOICE 100 Most Inspiring People

Read More »
July 22nd, 2021

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
May 3rd, 2021

Shear Insights: Peer-Reviewed Journal Publishes the Discovery of HemoShear’s HST5040 Small Molecule in Clinical Development for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
April 21st, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Read More »
March 31st, 2021

Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
February 22nd, 2021

BioCentury: $40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech 

Read More »
February 10th, 2021

HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

Read More »
January 28th, 2021

HemoShear announces appointment of Vice Presidents

Read More »
December 16th, 2020

HemoShear Therapeutics’ HST5040 Receives U.S. Orphan Drug Designations for Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
December 10th, 2020

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

Read More »
November 30th, 2020

Shear Insights: HemoShear Therapeutics to Present at Piper Sandler Annual Healthcare Conference

Read More »
View More +


HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902